Rare diseases are a good excuse to acquire small companies for little money. Due to not growing pipeline, a new plan for apparent growth is to acquire a few for millions each and flash a new expanding pipeline. Call this sustainability.
Layoff at AI and digital dept. They supposed to be a driver of progress not a failure. This shows that the AI and digital transformation are challenging projects and need attention and patience.
Layoff at AI and digital dept. They supposed to be a driver of progress not a failure. This show that the AI and digital transformation are challenging projects and need attention and patience.
Gilead sticks to DEI, thinking it is immune to competition who can run business more efficiently after dropping DEI. This is a typical pharma arrogance syndrome, with business not run efficiently, under excuse of specific nature of healthcare. The cost is passed on patients, healthcare system and overall on all premium and tax payers, pharma being one of the leaches. Time to have more DOGE-like bodies to reform the whole system. Sounds impossible? Would result in 20-30% reduction of employment and deportations.
New CEO task by Roche was to bring the stock price below $60, so Roche could consider an acquisition. It is getting there.
Even if Roche offers some premium, the investors would lose badly in comparison to the past valuation. The CEO has been busy on this, not on improving a quality of management team.
Astria sounds better than Catab.
We just got a person to help us who was a failure in Pfizer and a failure in Moderna. Hope he will not fail all of us.
